NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development

NEO100 reported six-month progression-free survival of 48.9% against a prespecified 20% benchmark in its 24-patient Phase 2a study.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) appointed Ali Alabedin to its Board of Directors effective October 9, 2026, succeeding Dr. Steven L. Giannotta. Giannotta will remain on the Scientific Advisory Board.

NEO212 completed Phase 1 dose escalation and is advancing toward Phase 2. Abu Dhabi granted investigational new drug authorization, subject to ethics approvals and other pre-enrollment conditions; it is not marketing approval or confirmation of enrollment. An FDA End-of-Phase 1 Type B meeting is scheduled for November 17, 2026.

The 24-patient NEO100 Phase 2a study reported six-month progression-free survival, meaning survival without disease worsening, of 48.9% versus a prespecified 20% benchmark, and median overall survival of 26.09 months. NeOnc also redeemed its outstanding Series A convertible preferred stock; the company said this eliminated associated potential dilution without issuing common shares.

5 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointNEO100 Phase 2a six-month progression-free survival reached 48.9% versus a prespecified 20% benchmark in 24 patients.
• Moderate point. Forward-looking: it has not happened yet and may not happen.NEO212 completed Phase 1 dose escalation and is advancing toward Phase 2.
• Moderate pointAbu Dhabi investigational new drug authorization supports NEO212 development in the UAE.
• Moderate pointSeries A preferred stock redemption eliminated associated potential dilution without common-share issuance, NeOnc said.
• Minor pointNEO100 Phase 2a median overall survival was 26.09 months.

Negative

• Minor pointUAE development remains subject to required ethics approvals and other pre-enrollment conditions.

Argus 15 min delay 5 alerts

+5.97% vs previous close $2.75 last price 0.9x rel. volume Open Argus

Details

Market move: NTHI +5.97% vs previous close. Board director appointment

$2.60 – $2.90 Day Range

$79.21M Market Cap

On Oct 14, the day this news came out, the latest delayed price for NTHI is 5.97% above the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $2.75.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Six-month progression-free survival: 48.9% vs. prespecified 20% benchmark Median overall survival: 26.09 months Study enrollment: 24 patients +1 more

Six-month progression-free survival

48.9% vs. prespecified 20% benchmark

NEO100 Phase 2a study

Median overall survival

26.09 months

NEO100 Phase 2a study

Study enrollment

24 patients

NEO100 Phase 2a study

FDA meeting

November 17, 2026

End-of-Phase 1 Type B meeting regarding NEO212

Key Terms

blood-brain barrier, investigational new drug authorization, progression-free survival, convertible preferred stock

4 terms

blood-brain barrier medical

"delivering therapies across the blood-brain barrier"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

investigational new drug authorization regulatory

"granted investigational new drug authorization supporting development in the UAE"

A regulatory permission from a drug-safety agency that authorizes a sponsor to begin or expand clinical testing of a new drug or biological product in humans. The authorization is granted after the sponsor submits safety, manufacturing (chemistry, manufacturing and controls), and clinical-protocol information so regulators can assess whether planned trials can be conducted without unreasonable risk; it allows clinical use for research purposes only and is not a marketing approval. The authorization can be limited, placed on hold, or withdrawn if the regulator identifies safety or data-quality problems.

progression-free survival medical

"reporting six-month progression-free survival of 48.9%"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

convertible preferred stock financial

"redemption of its outstanding Series A convertible preferred stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom, while its clinical-development progress seeks to advance treatments for some of the most difficult cancers to treat. The clinical-stage biopharmaceutical company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026, adding more than three decades of international banking, governance and business leadership experience.

“Ali’s appointment strengthens our Board as we advance our clinical programs and build our presence in Abu Dhabi,” said Amir Heshmatpour, NeOnc’s executive chairman, president and chief executive officer. Alabedin succeeds Dr. Steven L. Giannotta, who has stepped down from the board but will continue serving on NeOnc’s Scientific Advisory Board, preserving his scientific contribution while the company adds financial and international-growth expertise.

The appointment comes as NeOnc pursues a broader development strategy for its NEO drug platform, designed to address the challenge of delivering therapies across the blood-brain barrier. One of the company’s central programs, NEO212, has completed Phase 1 dose escalation and is advancing toward Phase 2. The Department of Health – Abu Dhabi granted investigational new drug authorization supporting development in the UAE, subject to required ethics approvals and other pre-enrollment conditions. That opens a potential route to regional clinical development, but it does not constitute marketing approval or confirm that patient enrollment has begun.

NeOnc also reported a series of recent corporate and clinical milestones. On August 12, the company announced positive topline results from its 24-patient NEO100 Phase 2a study, reporting six-month progression-free survival of 48.9% against a prespecified 20% benchmark and median overall survival of 26.09 months. On September 17, it announced the redemption of its outstanding Series A convertible preferred stock, a capital-structure development the company said eliminated the associated potential dilution without issuing common shares.

The next major dates on the calendar include November 17, 2026, when NeOnc announced an End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration regarding NEO212. The discussions are expected to address potential Phase 2 trial design, patient population, endpoints and regulatory pathways. The meeting is a key opportunity to obtain regulatory feedback. Further milestones to watch include UAE ethics clearance and confirmation of NEO212 trial readiness, potential follow-up FDA engagement on NEO100 after its Phase 2a results.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeOnc's NEO100 Phase 2a study show?

The 24-patient NEO100 Phase 2a study reported six-month progression-free survival of 48.9% against a prespecified 20% benchmark. Median overall survival was 26.09 months.

When is NeOnc's NEO212 FDA meeting, and what will it cover?

NeOnc's End-of-Phase 1 Type B meeting with the FDA regarding NEO212 is scheduled for November 17, 2026. The company expects discussions to address potential Phase 2 trial design, patient population, endpoints and regulatory pathways.